^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Brain Cancer

    Related cancers:
    17h
    ONC206-001: Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms (clinicaltrials.gov)
    P1, N=102, Recruiting, Jazz Pharmaceuticals | Trial primary completion date: Dec 2025 --> Jul 2026
    Trial primary completion date • First-in-human
    |
    JZP3507
    20h
    Vorasidenib in Combination With Temozolomide (TMZ) in IDH-mutant Glioma (clinicaltrials.gov)
    P1/2, N=55, Recruiting, Institut de Recherches Internationales Servier | N=42 --> 55
    Enrollment change
    |
    temozolomide • Voranigo (vorasidenib)
    20h
    PNOC017: BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas (clinicaltrials.gov)
    P1, N=78, Active, not recruiting, University of California, San Francisco | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2)
    |
    IDH2 mutation
    |
    temozolomide • Partruvix (pamiparib)
    20h
    FDG PET/CT in Monitoring Very Early Therapy Response in Patients With Glioblastoma (clinicaltrials.gov)
    P=N/A, N=7, Completed, Jonsson Comprehensive Cancer Center | N=50 --> 7 | Trial completion date: Aug 2026 --> Jan 2025 | Trial primary completion date: Aug 2025 --> Jan 2025 | Recruiting --> Completed
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    22h
    NeuroPathways Intervention for Brain Tumor Patients (clinicaltrials.gov)
    P=N/A, N=50, Recruiting, Massachusetts General Hospital | Trial completion date: Apr 2026 --> Apr 2027 | Trial primary completion date: Sep 2025 --> Sep 2026
    Trial completion date • Trial primary completion date
    1d
    Observational Study for Assessing Treatment and Outcome of Patients With Primary Brain Tumours Using cIMPACT-NOW and 2021 WHO Classification (clinicaltrials.gov)
    P=N/A, N=1650, Recruiting, European Organisation for Research and Treatment of Cancer - EORTC | N=1250 --> 1650 | Trial completion date: Dec 2026 --> Jul 2038 | Trial primary completion date: Aug 2026 --> Dec 2027
    Enrollment change • Trial completion date • Trial primary completion date
    2d
    Accelerating Motor Recovery in Glioma Patients Using Postoperative nrTMS (clinicaltrials.gov)
    P=N/A, N=43, Active, not recruiting, Beijing Neurosurgical Institute
    New trial
    2d
    ReVoGlio: Vortioxetine for Newly Diagnosed Glioblastoma (clinicaltrials.gov)
    P2, N=78, Not yet recruiting, University of Zurich
    New P2 trial
    |
    temozolomide
    2d
    Somatic Mosaicism in Twins Discordant for Childhood Cancer (clinicaltrials.gov)
    P=N/A, N=50, Recruiting, Children's Oncology Group | Trial completion date: Dec 2025 --> Jun 2027 | Trial primary completion date: Oct 2025 --> Jun 2026
    Trial completion date • Trial primary completion date
    2d
    Fluorescence Enhanced Stereotactic Surgery (FESS) (clinicaltrials.gov)
    P=N/A, N=20, Recruiting, Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
    New trial
    2d
    Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma. (clinicaltrials.gov)
    P1, N=18, Recruiting, Henry Ford Health System | Trial completion date: Oct 2026 --> Dec 2027 | Trial primary completion date: Oct 2025 --> Jan 2027
    Trial completion date • Trial primary completion date